[Form 3] ABBOTT LABORATORIES Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

ABBOTT LABORATORIES Senior Vice President Orville Jacob A filed an initial ownership report showing 37,238 common shares held directly. These shares represent a restricted stock unit award with a four-year term, vesting in equal annual installments starting on February 25, 2027, with the ability to have shares withheld for taxes.

The report follows Abbott’s acquisition of Exact Sciences Corporation, where each Exact common share was converted into the right to receive $105.00 in cash. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock units based on this merger consideration and Abbott’s 10-day average share price before closing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ORVILLE JACOB A

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	37,238(1)(2)(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 23, 2026, Abbott Laboratories ("Abbott") acquired Exact Sciences Corporation ("Exact") pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the "Merger Agreement"), by and among Abbott, Exact and Badger Merger Sub I, Inc. ("Merger Sub"). Pursuant to the terms of, and subject to the conditions contained in, the Merger Agreement, Merger Sub merged with and into Exact, with Exact surviving as a direct, wholly owned subsidiary of Abbott (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.01 per share, of Exact ("Exact common stock") issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was automatically converted into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes (the "Merger Consideration").

2. Further, each restricted stock unit award granted under an Exact stock plan (each, an "RSU") on or after November 19, 2025, other than RSU awards granted to Exact's non-employee directors, was assumed by Abbott at the Effective Time as an Abbott restricted stock unit award on substantially the same terms and conditions as were applicable to the corresponding RSU award (including with respect to double-trigger vesting protections), with the number of Abbott common shares underlying such Abbott restricted stock unit award determined based on the Merger Consideration divided by the average closing price of an Abbott common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.

3. These shares represent a restricted stock unit award that has a 4-year term, with 1/4 of the award vesting each year, beginning on February 25, 2027. The award includes the right to have shares withheld for tax purposes.

	/s/ Jacob A. Orville by Jessica H. Paik, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What share holdings does Orville Jacob A report in Abbott (ABT)?

Orville Jacob A reports beneficial ownership of 37,238 Abbott common shares. These are in the form of a restricted stock unit award that vests over four years, beginning February 25, 2027, and allows shares to be withheld to cover applicable tax obligations.

How are Orville Jacob A’s Abbott (ABT) restricted stock units structured?

The restricted stock unit award has a four-year term with annual vesting. One quarter of the award vests each year starting February 25, 2027, and the structure includes the right to have a portion of shares withheld to satisfy tax requirements at vesting.

How did the Exact Sciences merger affect Abbott (ABT) equity awards?

Abbott’s merger with Exact Sciences converted each Exact share into $105.00 cash. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock units using the merger consideration and Abbott’s 10-day average share price before the merger’s effective time.

What cash consideration was paid per Exact Sciences share in the Abbott (ABT) deal?

Each Exact Sciences common share was converted into the right to receive $105.00 in cash. This amount was paid without interest and subject to applicable withholding taxes, as part of Abbott’s acquisition of Exact under the defined merger agreement terms.

When do the reported Abbott (ABT) restricted stock units begin vesting?

The restricted stock units begin vesting on February 25, 2027. From that date, one quarter of the total award vests each year over a four-year period, assuming continued satisfaction of the applicable terms and conditions of the award.